mAb-话题@MedSci

#mAb#

1302篇内容 | 2891人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1912492, encodeId=78ed191249224, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=FDA批准DANYELZA（naxitamab-gqgk）治疗神经母细胞瘤, objectType=article, longId=203778, objectId=2570203e7882, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2570203e7882, replyNumber=0, likeNumber=85, createdTime=2021-03-28, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2570203e7882, moduleTitle=FDA批准DANYELZA（naxitamab-gqgk）治疗神经母细胞瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2570203e7882)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912396, encodeId=2da519123966a, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=百济神州PD-1单抗Tislelizumab治疗肝细胞癌的新药申请被NMPA接受，以及Tislelizumab抗肿瘤临床研究汇总, objectType=article, longId=196984, objectId=1327196984da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1327196984da, replyNumber=0, likeNumber=102, createdTime=2020-08-15, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1327196984da, moduleTitle=百济神州PD-1单抗Tislelizumab治疗肝细胞癌的新药申请被NMPA接受，以及Tislelizumab抗肿瘤临床研究汇总, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1327196984da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912459, encodeId=44901912459c6, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Blood：Floteuzumab挽救治疗免疫治疗难治性急性髓系白血病, objectType=article, longId=202251, objectId=2ea82022518b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2ea82022518b, replyNumber=0, likeNumber=71, createdTime=2021-08-07, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2ea82022518b, moduleTitle=Blood：Floteuzumab挽救治疗免疫治疗难治性急性髓系白血病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2ea82022518b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912580, encodeId=745519125805d, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=NEJM：Nivolumab辅助治疗方案用于晚期食管或胃食管交界癌患者III期临床研究获得成功, objectType=article, longId=209558, objectId=b719209558c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b719209558c2, replyNumber=0, likeNumber=67, createdTime=2021-04-10, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b719209558c2, moduleTitle=NEJM：Nivolumab辅助治疗方案用于晚期食管或胃食管交界癌患者III期临床研究获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b719209558c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912539, encodeId=e7de1912539c5, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Blood：Flotetuzumab作为难治性AML患者的补救免疫疗法的疗效和安全性, objectType=article, longId=207128, objectId=b43f20e12849, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b43f20e12849, replyNumber=0, likeNumber=78, createdTime=2021-08-12, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b43f20e12849, moduleTitle=Blood：Flotetuzumab作为难治性AML患者的补救免疫疗法的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b43f20e12849)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912611, encodeId=b9301912611a2, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Lancet Oncology：Avelumab联合同步放化疗与单纯同步放化疗治疗局部晚期头颈部鳞状细胞癌：一项随机、双盲、安慰剂对照、多中心、3期试验 , objectType=article, longId=212089, objectId=fc5c2120893c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc5c2120893c, replyNumber=0, likeNumber=43, createdTime=2022-01-08, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc5c2120893c, moduleTitle=Lancet Oncology：Avelumab联合同步放化疗与单纯同步放化疗治疗局部晚期头颈部鳞状细胞癌：一项随机、双盲、安慰剂对照、多中心、3期试验 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fc5c2120893c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912582, encodeId=6b66191258269, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle= Blood：Inotuzumab ozogamicin用于复发/难治性小儿急性淋巴细胞白血病的疗效, objectType=article, longId=209725, objectId=06c7209e2530, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=06c7209e2530, replyNumber=0, likeNumber=68, createdTime=2022-01-02, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=06c7209e2530, moduleTitle= Blood：Inotuzumab ozogamicin用于复发/难治性小儿急性淋巴细胞白血病的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=06c7209e2530)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912462, encodeId=cb6c1912462f2, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Lancet respir med：Pembrolizumab联合放疗用于转移性非小细胞肺癌患者的治疗, objectType=article, longId=202368, objectId=85c8202368f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=85c8202368f2, replyNumber=0, likeNumber=96, createdTime=2021-02-03, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=85c8202368f2, moduleTitle=Lancet respir med：Pembrolizumab联合放疗用于转移性非小细胞肺癌患者的治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=85c8202368f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912425, encodeId=e43f191242542, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Itolizumab治疗急性GVHD：取得积极结果, objectType=article, longId=199211, objectId=265e199211c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=265e199211c6, replyNumber=0, likeNumber=69, createdTime=2020-12-31, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=265e199211c6, moduleTitle=Itolizumab治疗急性GVHD：取得积极结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=265e199211c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912480, encodeId=ed641912480a0, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=阿斯利康的TSLP单抗tezepelumab治疗严重哮喘，III期临床成功, objectType=article, longId=203246, objectId=d0c62032469d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d0c62032469d, replyNumber=0, likeNumber=107, createdTime=2021-08-13, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d0c62032469d, moduleTitle=阿斯利康的TSLP单抗tezepelumab治疗严重哮喘，III期临床成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d0c62032469d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912428, encodeId=37b919124288d, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Blood：Emicizumab治疗获得性血友病A, objectType=article, longId=199478, objectId=3c8b1994e856, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3c8b1994e856, replyNumber=0, likeNumber=78, createdTime=2021-04-26, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3c8b1994e856, moduleTitle=Blood：Emicizumab治疗获得性血友病A, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3c8b1994e856)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912497, encodeId=9f97191249e65, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Lancet Neurology：ORATORIO试验的长期随访：早期和持续ocrelizumab治疗对原发性进行性MS的疾病进展具有益处, objectType=article, longId=204334, objectId=30c92043341a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=30c92043341a, replyNumber=0, likeNumber=88, createdTime=2021-02-28, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=30c92043341a, moduleTitle=Lancet Neurology：ORATORIO试验的长期随访：早期和持续ocrelizumab治疗对原发性进行性MS的疾病进展具有益处, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=30c92043341a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912461, encodeId=970319124618c, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=ESID 2020：敏感性分析证实了Emapalumab治疗噬血细胞性淋巴组织细胞增多症（HLH）的功效, objectType=article, longId=202282, objectId=8ace202282a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8ace202282a7, replyNumber=0, likeNumber=72, createdTime=2021-05-18, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8ace202282a7, moduleTitle=ESID 2020：敏感性分析证实了Emapalumab治疗噬血细胞性淋巴组织细胞增多症（HLH）的功效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8ace202282a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912594, encodeId=105419125941c, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=NEJM：Donanemab治疗早期阿尔茨海默病临床研究获得积极结果, objectType=article, longId=210903, objectId=bcfc210903e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bcfc210903e7, replyNumber=0, likeNumber=70, createdTime=2021-09-15, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bcfc210903e7, moduleTitle=NEJM：Donanemab治疗早期阿尔茨海默病临床研究获得积极结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bcfc210903e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912575, encodeId=568519125e540, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=EMA就使用regdanvimab治疗COVID-19，持谨慎意见, objectType=article, longId=209108, objectId=9faa2091087c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9faa2091087c, replyNumber=0, likeNumber=63, createdTime=2021-05-05, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9faa2091087c, moduleTitle=EMA就使用regdanvimab治疗COVID-19，持谨慎意见, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9faa2091087c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912413, encodeId=f9f519124131c, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Arthritis Rheumatol：Canakinumab在5岁及以下CAPS患者中的治疗作用, objectType=article, longId=198102, objectId=91da198102bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=91da198102bf, replyNumber=0, likeNumber=92, createdTime=2020-09-21, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=91da198102bf, moduleTitle=Arthritis Rheumatol：Canakinumab在5岁及以下CAPS患者中的治疗作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=91da198102bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912577, encodeId=497619125e7b9, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=再次遇阻，辉瑞与礼来的骨关节炎止痛药Tanezumab能否迎来曙光？, objectType=article, longId=209235, objectId=8586209235f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8586209235f2, replyNumber=0, likeNumber=75, createdTime=2022-02-27, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8586209235f2, moduleTitle=再次遇阻，辉瑞与礼来的骨关节炎止痛药Tanezumab能否迎来曙光？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8586209235f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912486, encodeId=6d5c1912486de, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=全球**纳米抗体Caplacizumab继FDA、EMA之后，再次获得NICE批准治疗罕见病患者的凝血障碍, objectType=article, longId=203477, objectId=04852034e7dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=04852034e7dd, replyNumber=0, likeNumber=86, createdTime=2020-12-23, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=04852034e7dd, moduleTitle=全球**纳米抗体Caplacizumab继FDA、EMA之后，再次获得NICE批准治疗罕见病患者的凝血障碍, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=04852034e7dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912379, encodeId=1f9219123e92a, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=2020EAN大会速递丨Satralizumab在NMOSD患者中的PK/PD特征支持其给药方案, objectType=article, longId=195607, objectId=c7a119560ea0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c7a119560ea0, replyNumber=0, likeNumber=63, createdTime=2021-02-13, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c7a119560ea0, moduleTitle=2020EAN大会速递丨Satralizumab在NMOSD患者中的PK/PD特征支持其给药方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c7a119560ea0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912515, encodeId=ade71912515b3, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=慢性自发性荨麻疹(CSU)新药！诺华新一代IgE抗体ligelizumab获美国FDA突破性药物资格!, objectType=article, longId=205804, objectId=2e6320580469, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2e6320580469, replyNumber=0, likeNumber=73, createdTime=2021-10-01, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2e6320580469, moduleTitle=慢性自发性荨麻疹(CSU)新药！诺华新一代IgE抗体ligelizumab获美国FDA突破性药物资格!, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2e6320580469)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

mAb

2020-05-29

snf701207 (审核中...)

前往app查看评论内容

#mAb#

FDA批准DANYELZA（naxitamab-gqgk）治疗神经母细胞瘤

2021-03-28

智者为医08 (审核中...)

前往app查看评论内容

#mAb#

百济神州PD-1单抗Tislelizumab治疗肝细胞癌的新药申请被NMPA接受，以及Tislelizumab抗肿瘤临床研究汇总

2020-08-15

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Blood：Floteuzumab挽救治疗免疫治疗难治性急性髓系白血病

2021-08-07

snf701207 (审核中...)

前往app查看评论内容

#mAb#

NEJM：Nivolumab辅助治疗方案用于晚期食管或胃食管交界癌患者III期临床研究获得成功

2021-04-10

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Blood：Flotetuzumab作为难治性AML患者的补救免疫疗法的疗效和安全性

2021-08-12

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Lancet Oncology：Avelumab联合同步放化疗与单纯同步放化疗治疗局部晚期头颈部鳞状细胞癌：一项随机、双盲、安慰剂对照、多中心、3期试验

2022-01-08

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Blood：Inotuzumab ozogamicin用于复发/难治性小儿急性淋巴细胞白血病的疗效

2022-01-02

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Lancet respir med：Pembrolizumab联合放疗用于转移性非小细胞肺癌患者的治疗

2021-02-03

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Itolizumab治疗急性GVHD：取得积极结果

2020-12-31

snf701207 (审核中...)

前往app查看评论内容

#mAb#

阿斯利康的TSLP单抗tezepelumab治疗严重哮喘，III期临床成功

2021-08-13

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Blood：Emicizumab治疗获得性血友病A

2021-04-26

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Lancet Neurology：ORATORIO试验的长期随访：早期和持续ocrelizumab治疗对原发性进行性MS的疾病进展具有益处

2021-02-28

snf701207 (审核中...)

前往app查看评论内容

#mAb#

ESID 2020：敏感性分析证实了Emapalumab治疗噬血细胞性淋巴组织细胞增多症（HLH）的功效

2021-05-18

智智灵药 (审核中...)

前往app查看评论内容

#mAb#

NEJM：Donanemab治疗早期阿尔茨海默病临床研究获得积极结果

2021-09-15

snf701207 (审核中...)

前往app查看评论内容

#mAb#

EMA就使用regdanvimab治疗COVID-19，持谨慎意见

2021-05-05

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Arthritis Rheumatol：Canakinumab在5岁及以下CAPS患者中的治疗作用

2020-09-21

snf701207 (审核中...)

前往app查看评论内容

#mAb#

再次遇阻，辉瑞与礼来的骨关节炎止痛药Tanezumab能否迎来曙光？

2022-02-27

snf701207 (审核中...)

前往app查看评论内容

#mAb#

全球**纳米抗体Caplacizumab继FDA、EMA之后，再次获得NICE批准治疗罕见病患者的凝血障碍

2020-12-23

snf701207 (审核中...)

前往app查看评论内容

#mAb#

2020EAN大会速递丨Satralizumab在NMOSD患者中的PK/PD特征支持其给药方案

2021-02-13

snf701207 (审核中...)

前往app查看评论内容

#mAb#

慢性自发性荨麻疹(CSU)新药！诺华新一代IgE抗体ligelizumab获美国FDA突破性药物资格!

2021-10-01

科室
- - 订阅+
  - 更多科室
工具
服务